New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Tumor volume and CP score were top predictors of OS, along with liver gross tumor volume, functional liver volume V20, and prior liver-directed therapy.

Blocking a key metabolic enzyme helps B cells fight liver tumors, revealing a new immunotherapy pathway for fatty liver–driven cancer in mice.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Plasma samples showed an association between suppressed extracellular vesicles and an increased risk for liver cancer.

Over 80% of hepatocellular carcinoma (HCC) – the third-leading cause of cancer deaths globally – emerges from advanced liver fibrosis or cirrhosis. A comprehensive review in Hepatology International ...

More than 500,000 annual liver cancer diagnoses could be prevented with global interventions aimed at reducing viral hepatitis B and C, alcohol consumption and a disease strongly associated with ...

The liver is the largest internal organ of the human body. This vital organ is crucial for the processes of digestion, ...

Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Nature featuring groundbreaking preclinical data for the treatment ...

Certain foods and nutrients were found to influence the risk of developing liver cancer. For example, aflatoxins (toxins from ...

Chronic liver disease is a pressing global health issue marked by persistent liver inflammation and damage which can progress to diseases such as fibrosis, cirrhosis, liver failure, or hepatocellular ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of ...